Avutometinib + Sotorasib
KRAS G12C-Mutant NSCLC
Phase 1/2Active (RAMP 203)
Key Facts
About Verastem Oncology
Verastem Oncology is on a mission to ensure no cancer patient runs out of treatment options by developing novel therapies for RAS/MAPK pathway-driven cancers, which are implicated in nearly a third of all cancers. The company achieved a significant milestone with the FDA approval of its combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Its clinical strategy is powered by a robust portfolio of ongoing trials and strategic collaborations, focusing on avutometinib as a backbone therapy in combination with agents like the FAK inhibitor defactinib to block compensatory pathways and drive deeper, more durable responses.
View full company profileTherapeutic Areas
Other KRAS G12C-Mutant NSCLC Drugs
| Drug | Company | Phase |
|---|---|---|
| Avutometinib + Adagrasib | Verastem Oncology | Phase 1/2 |